<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787527</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0484</org_study_id>
    <nct_id>NCT00787527</nct_id>
  </id_info>
  <brief_title>SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I/II of Vorinostat Plus CHOP in Untreated T-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find out how well the drug Zolinza
      (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide,
      doxorubicin, vincristine, and prednisone) to treat patients with untreated T-cell
      Non-Hodgkin's Lymphoma (NHL). The safety of these drugs in combination and the best dose of
      vorinostat when given in combination with CHOP will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Vorinostat is designed to cause chemical changes in different groups of proteins that are
      attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or
      cause the cancer cells to die.

      Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may
      slow or stop their growth. This may cause the cancer cells to die.

      Doxorubicin is designed to stop the growth of cancer cells, which may cause the cells to die.

      Vincristine is designed to interfere with the multiplication of cancer cells, which may slow
      or stop their growth. This may cause the cancer cells to die.

      Prednisone is designed to decrease inflammation by preventing white blood cells from
      completing an inflammatory reaction. This drug can cause lymphocytes, a type of white blood
      cell, to break apart and die.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will begin to take vorinostat
      on the first day of treatment which is Day -1. Vorinostat capsules are taken by mouth, either
      3 times a day or 2 times a day, depending on what the study doctor thinks is in your best
      interest. If you are taking vorinostat 3 times a day, it should be taken in the morning,
      afternoon and evening. If you are taking vorinostat 2 times a day, you will take the capsules
      in the morning and evening. The capsules must be taken with food (within 30 minutes after a
      meal). You will receive the vorinostat capsules on the first day of each cycle. You will also
      receive instructions on how to take the drug. You should return any unused vorinostat
      capsules back to study staff at the end of each cycle. You will take vorinostat for 5 days
      (Days -1 through 3) of each cycle and then beginning on Day 1, cyclophosphamide, vincristine,
      and doxorubicin will be given though a needle in your vein. This will happen for each 21-day
      study cycle. Cyclophosphamide is given over 1 hour. Vincristine is given over 15 minutes.
      Doxorubicin is also given over 15 minutes.

      The starting dose of vorinostat may change On Days 1-5 of each cycle, you will take
      prednisone tablets by mouth.

      If you begin to experience severe or intolerable side effects, the study drug schedule may be
      stopped for up to 3 weeks. If the side effects improve, you may be able to receive the study
      drugs again, with either a lower dose of vorinostat or if you are taking vorinostat three
      times daily, you may take it twice a day instead. The chemotherapy drugs (cyclophosphamide,
      doxorubicin, vincristine, and prednisone) may also be lowered depending on what side effects
      are being experienced. If you continue to have severe or intolerable side effects with the
      lower dose of vorinostat and chemotherapy, you will taken off study.

      Study Visits:

      On Day 1 of all cycles, the following tests and procedures will be performed:

        -  Your medical history will be recorded, including any drugs that you are taking.

        -  You will be asked about any side effects you may have experienced.

        -  You will have a physical exam, including measurement of your vital signs and weight.

        -  Blood (about 5 teaspoons) will be drawn for routine tests.

        -  Your performance status will be recorded.

      On Day 1 of Cycle 2 you will have an ECG.

      On or before Day 1 of Cycle 3 the following tests and procedures will be performed if your
      doctor thinks necessary:

        -  You will have CT and/or PET scans to check the status of the disease.

        -  You may have a bone marrow aspirate and/or biopsy to check the status of the disease.

      Length of Study:

      You will receive the study drugs for up to 6 cycles. You may be taken off study early if the
      disease gets worse or if severe or intolerable side effects occur.

      End-of-Study Visit:

      If you go off study treatment for any reason, you will have an end-of-study visit within 4
      weeks after your last dose of study drugs or before starting a new treatment. At this visit,
      the following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs.

        -  Your performance status will be recorded.

        -  You will be asked about any side effects you may have experienced.

        -  Blood (about 5 teaspoons) will be drawn for routine tests.

        -  You will have CT scans and PET scans to check the status of the disease.

        -  If you had skin lesions when you began the study, the skin lesions will be photographed.

        -  If the doctor thinks it is needed, you will have bone marrow biopsy and/or aspirate.

      Follow-up Visits:

      After you are off study treatment, you will have follow-up visits. You will go to these
      visits every 3 months for the1st year, every 4 months for the 2nd and 3rd years, and every 6
      months for the 4th and 5th years. After this, you will return 1 time each year unless the
      lymphoma returns. The following tests and procedures will be performed:

        -  You will have a physical exam, including measurement of your vital signs.

        -  Your performance status will be recorded

        -  You will be asked about any side effects you may have experienced.

        -  Blood (about 5 teaspoons) will be drawn for routine tests.

        -  You will have CT scans and PET scans to check the status of the disease.

        -  If you had skin lesions when you began the study, the skin lesions will be photographed.

        -  If the doctor thinks it is needed, you will have bone marrow biopsy and/or aspirate.

      This is an investigational study. Vorinostat is FDA approved and commercially available for
      the treatment of cutaneous T-cell lymphoma that has not come back or not responded to prior
      therapy. CHOP is currently FDA approved for treatment of patients with NHL. The use of
      vorinostat in combination with CHOP in patients with T-cell NHL is investigational.

      Up to 52 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Maximum Tolerated Dose (MTD) of Vorinostat</measure>
    <time_frame>21 Days</time_frame>
    <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); and for Phase II Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat</measure>
    <time_frame>21 Days</time_frame>
    <description>MTD of Vorinostat defined as highest dose level in which 6 patients have been treated with less than 2 instances of DLT. Continual reassessment during each 21-day cycle to assess DLT. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle. The dose of Vorinostat escalated in successive 3+3 cohorts of participants to determine the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II MTD of Vorinostat</measure>
    <time_frame>21 Days</time_frame>
    <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolinza (vorinostat)</intervention_name>
    <description>Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.</description>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
    <other_name>vorinostat</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>MSK-390</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle</description>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
    <other_name>AD</other_name>
    <other_name>Hydroxydaunomycin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle</description>
    <arm_group_label>Zolinza + CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have a new diagnosis of T-cell NHL eligible histologies
             include:Peripheral T-cell lymphoma (unspecified), CD 30 + anaplastic large cell
             lymphoma (ALK) (ALK-1 positive and ALK-1 negative), angioimmunoblastic T-cell
             lymphoma, intestinal T-cell lymphoma, subcutaneous panniculitic T-cell lymphoma.

          2. Patients who are eligible for blood and marrow transplant can receive this treatment
             to maximal reduction of tumor bulk. A minimum of four cycles of therapy will be given
             before evaluation for to hematopoetic stem cell transplant.

          3. Patients must have biopsy proven disease which can include bone marrow and/or lymph
             node (cutaneous only disease is excluded)

          4. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0
             to 2.

          5. Patients must be age 18 years old and above.There is no dosing or adverse event data
             are currently available on the use of vorinostat in patients &lt;18 years of age,
             children are excluded from this study but may be eligible for future pediatric phase 2
             combination trials.

          6. There is Patients are required to have adequate bone marrow reserve as indicated:
             Absolute neutrophil count (ANC) &gt;/= 1000/mm^3, Platelets &gt;/= 50,000/mm3, Hemoglobin
             &gt;/= 8g/dL. If there is bone marrow involvement by lymphoma then there is no minimum
             level of counts required.

          7. Patients must have adequate liver function as indicated by: Bilirubin &lt;/= 1.5 times
             the upper limit of normal (ULN), Alanine transaminase (ALT) &lt;/=2 times the (ULN) or
             aspartate transaminase (AST) &lt;/= 2 times the ULN. These values must be obtained within
             two weeks before protocol entry.

          8. Patients are required to have adequate renal function as indicated by a serum
             creatinine &lt;/= 2.5 mg/dL. This value must be obtained within two weeks before protocol
             entry.

          9. Left ventricular ejection fraction must be evaluated by nuclear medicine scan or
             echocardiography and measure &gt;/= 50%.

         10. Concomitant steroids may continue provided they are being used for symptom management
             and not for treatment of lymphoma.

         11. Male patients must agree to use a barrier method of contraception or agree to abstain
             from heterosexual activity for the duration of the study

         12. Female patients must be willing to use two adequate barrier methods of contraception
             to prevent pregnancy or agree to abstain from heterosexual activity throughout the
             study or be post menopausal (free from menses &gt; two years or surgically sterilized).

         13. Female patients of childbearing potential must have a negative serum pregnancy test
             (Beta human chorionic gonadotropin (hCG)) within 72 hours of receiving the first dose
             of vorinostat.

         14. Patients must have the ability able to give informed consent.

        Exclusion Criteria:

          1. 1. Patients with a) T-cell lymphoma with skin involvement only are excluded if they
             have no evidence of systemic disease b)T-cell prolymphocytic leukemia (T-PLL) c)
             T-cell large granular lymphocytic leukemia d) Primary cutaneous CD30+ disorders:
             anaplastic large cell lymphoma and lymphomatoid papulosis e) Angiocentric/nasal type
             T/Natural Killer (NK)-cell lymphoma f) Hepatosplenic gamma-delta T-cell lymphoma

          2. Patients with active Hepatitis B and/or Hepatitis C infection.

          3. Patients with known HIV infection are excluded. a) These patients are excluded
             secondary to potential to target activated T-cells, in a population of patients
             already at risk for T-cell depletion, would be a contraindication to therapy.

          4. Patients with active infections requiring specific anti-infective therapy are not
             eligible until all signs of infections are resolved.

          5. Patients with pre-existing cardiovascular disease requiring ongoing treatment. This
             includes:a) Congestive heart failure, b) Severe CAD, c) Cardiomyopathy, d)
             Uncontrolled cardiac arrhythmia, e) Unstable angina pectoris, f) Recent MI (within 6
             months).

          6. Patients with prior exposure to either vorinostat (including other histone deacetylase
             (HDAC) inhibitors except valproic acid) or anthracyclines: a) Patients who have
             received valproic acid (VPA) for the treatment of seizures may be enrolled on this
             study, but must not have received VPA within 30 days of study enrollment.

          7. Patients who are pregnant or breast-feeding. a)Effects of this treatment on the fetus
             and young children are unknown at this time.

          8. Patients who have had an invasive solid tumor malignancy in the past five years except
             non-melanoma skin cancers or cervical carcinoma in situ or ductal/lobular carcinoma in
             situ of the breast who is currently without evidence of disease.

          9. Patients undergoing anti-neoplastic chemotherapy, radiation, hormonal (excluding
             contraceptives) or immunotherapy, or investigational medications within the past four
             weeks.

         10. Patients with deep vein thrombosis within three months.

         11. Patient with concurrent use of complementary or alternative medicines.

         12. Patients with psychiatric illness and/or social situations that would limit compliance
             with the study medication and requirements.

         13. Patients with grade 2 or more neuropathy.

         14. Patients with known central nervous system (CNS) lymphoma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasuhiro Oki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas (UT) MD Anderson Cancer Center official website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>September 2, 2014</results_first_submitted>
  <results_first_submitted_qc>September 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <last_update_submitted>September 2, 2014</last_update_submitted>
  <last_update_submitted_qc>September 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>SAHA</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Suberoylanilide Hydroxamic Acid</keyword>
  <keyword>MSK-390</keyword>
  <keyword>CHOP</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>AD</keyword>
  <keyword>Hydroxydaunomycin hydrochloride</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Untreated T-cell</keyword>
  <keyword>T-cell NHL</keyword>
  <keyword>Peripheral T-cell lymphoma</keyword>
  <keyword>PTCL</keyword>
  <keyword>CD 30</keyword>
  <keyword>Anaplastic large cell lymphoma</keyword>
  <keyword>Angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>Intestinal T-cell lymphoma</keyword>
  <keyword>Subcutaneous panniculitic T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 04/03/09 to 12/19/12. All participants were recruited at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zolinza + CHOP</title>
          <description>Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin: 50 mg/m^2 by vein/intravenous (IV) over 15 minutes on Day 1 of 21 day cycle
Prednisone: 100 mg tablets by mouth/orally (PO) once a day on Days 1-5 of 21 day cycle
Zolinza (vorinostat): Phase I Starting dose of 300 mg by mouth each evening on Days 5-14 of 21 day cycle.
Cyclophosphamide: 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zolinza + CHOP</title>
          <description>Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin : 50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Zolinza (vorinostat) : Starting oral dose (Schedule A) of 300 mg once a day on Days 5-14 of 21 day cycle.
Cyclophosphamide : 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="29" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vorinostat Treatment (Schedule A/Schedule B)</title>
          <description>Number of participants who received either Vorinostat treatment Schedule A (300 mg once daily or 200 mg twice daily) for Phase I or Schedule B (300 mg three times daily) for Phase II.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>300 mg once daily on Days 5 to14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>200 mg twice daily on Days 5 to14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>300 mg three times daily on Days -2 to 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase I Maximum Tolerated Dose (MTD) of Vorinostat</title>
        <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); and for Phase II Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
        <time_frame>21 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Schedule A - Vorinostat Once or Twice Daily</title>
            <description>Vorinostat 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle) on Days 5-14 of 21 day cycle or Vorinostat 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle) on Days 5-14 of 21 day cycle
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin : 50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Cyclophosphamide : 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase I Maximum Tolerated Dose (MTD) of Vorinostat</title>
          <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); and for Phase II Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
          <units>mg/day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat</title>
        <description>MTD of Vorinostat defined as highest dose level in which 6 patients have been treated with less than 2 instances of DLT. Continual reassessment during each 21-day cycle to assess DLT. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle. The dose of Vorinostat escalated in successive 3+3 cohorts of participants to determine the MTD.</description>
        <time_frame>21 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Schedule A - Vorinostat Once Daily</title>
            <description>Vorinostat 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle) on Days 5-14 of 21 day cycle
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin : 50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Cyclophosphamide : 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
          </group>
          <group group_id="O2">
            <title>Schedule A - Vorinostat Twice Daily</title>
            <description>Vorinostat 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle) on Days 5-14 of 21 day cycle
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin : 50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Cyclophosphamide : 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat</title>
          <description>MTD of Vorinostat defined as highest dose level in which 6 patients have been treated with less than 2 instances of DLT. Continual reassessment during each 21-day cycle to assess DLT. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle. The dose of Vorinostat escalated in successive 3+3 cohorts of participants to determine the MTD.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II MTD of Vorinostat</title>
        <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
        <time_frame>21 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Schedule B - Vorinostat Three Times Daily</title>
            <description>Vorinostat administered orally 300 mg three times daily from days -2 to 3 (4500 mg over 5 days per cycle) of 21 day cycle.
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Doxorubicin : 50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
Prednisone : 100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
Cyclophosphamide : 750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
Vincristine : 1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II MTD of Vorinostat</title>
          <description>MTD of Vorinostat when administered in combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) defined as highest dose level in which 6 patients have been treated with less than 2 instances of dose limiting toxicity (DLT). Continual reassessment during each 21-day cycle to assess dose limiting toxicity. Two schedules of Vorinostat were investigated: Phase I A) daily doses on days 5 to 14, or Phase II B) three times a day on days -2 to 3 of standard CHOP every 21 days. Vorinostat was administered orally on days 5 to 14 (Schedule A), first at 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), and next at 200 mg orally twice daily (total doses of 4000 mg over 10 days per cycle); Schedule B Vorinostat administered orally 300 mg orally three times daily from days -2 to 3 (4500 mg over 5 days per cycle).</description>
          <units>mg/three times daily</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting period begins once study drug treatment is initiated through 30 days after the last study treatment (21 day cycle). Overall study participation July 2009 to August 2012 for Phase I (Schedule A) and Phase II (Schedule B).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Schedule A: Vorinostat Once or Twice Daily</title>
          <description>Phase I: Vorinostat administered Days 5 to 14 at starting dose 300 mg orally once daily (total doses of 3000 mg over 10 days per cycle), next administered dose 200 mg orally twice daily (4000 mg over 10 days per cycle).
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for 21 day cycle: Doxorubicin 50 mg/m^2 IV Day 1; Prednisone 100 mg tablets orally/day Days 1-5; Cyclophosphamide 750 mg/m^2 IV Day 1; Vincristine 1.4 mg/m^2 IV Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Schedule B: Vorinostat Three Times Daily</title>
          <description>Phase II: Vorinostat administered at starting dose 300 mg orally three times daily from Days -2 to 3 (4500 mg over 5 days per cycle).
Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for 21 day cycle: Doxorubicin 50 mg/m^2 IV Day 1; Prednisone 100 mg tablets orally/day Days 1-5; Cyclophosphamide 750 mg/m^2 IV Day 1; Vincristine 1.4 mg/m^2 IV Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral Mucositis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Other infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yasuhiro Oki, MD/ Associate Professor</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-2860</phone>
      <email>yoki@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

